ECC4703 / Eccogene - LARVOL DELTA

Eccogene Announces First Patient Enrolled in MIST Phase 2a Trial Evaluating ECC4703 as an Adjunct to Semaglutide for the Treatment of Obesity (Businesswire) - "MIST (Metabolic Intervention with Semaglutide and THR-β) is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial expected to enroll approximately 160 adults with obesity. The primary endpoints include changes in body weight and liver fat content as assessed by MRI-PDFF."

Trial status • Obesity

ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Eccogene | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis

ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Eccogene

New P1 trial • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) (clinicaltrials.gov) - P2 | N=160 | Recruiting | Sponsor: Eccogene | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • APOB

Eccogene Announces First Patient Enrolled in MOSAIC Phase 2a Trial Evaluating ECC4703 and ECC0509, Individually and in Combination, for the Treatment of MASH (Businesswire) - "The study will enroll approximately 160 participants, with change in liver fat content assessed by MRI-PDFF as the primary endpoint."

Trial status • Metabolic Dysfunction-Associated Steatohepatitis

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) (clinicaltrials.gov) - P2 | N=160 | Not yet recruiting | Sponsor: Eccogene

New P2 trial • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • APOB

SYNERGISTIC EFFECTS OF ECC4703, A LIVER-TARGETING THRΒ FULL AGONIST, IN COMBINATION WITH ECC0509, A SELECTIVE SSAO INHIBITOR, OR SEMAGLUTIDE IN A MASH ANIMAL MODEL (AASLD 2025) - "ECC4703 has the potential to be the corner stone for combination with other mechanisms to treat MASH in humans."

Combination therapy • Preclinical • Diabetes • Fibrosis • Genetic Disorders • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity

Eccogene Receives U.S. FDA Clearance to Initiate Phase 2a MOSAIC Trial of ECC4703 and ECC0509 for MASH (GlobeNewswire) - "The MOSAIC trial is a U.S.-based, multicenter, randomized, double-blind, placebo-controlled Phase 2a trial that will evaluate the efficacy and safety of ECC4703, ECC0509, and the combination of the two in adults with presumed MASH. The 12-week study is expected to enroll approximately 160 participants."

IND • New P2a trial • Metabolic Dysfunction-Associated Steatohepatitis

Metabolic Effects of ECC4703, a Liver Targeting Full THRb Agonist, in Combination with Semaglutide and Tirzepatide in Diet-Induced Obese Mice (ADA 2025) - "These results suggest that ECC4703 in combination with GLP-1R agonists holds potential therapeutic merits to treat obesity and related comorbidities."

Combination therapy • Late-breaking abstract • Preclinical • Metabolic Disorders • Obesity

Eccogene to Report Preclinical Data with ECC4703, Showcasing Impact on Lean Muscle Sparing and Fat Loss in Combination with Semaglutide and Tirzepatide (GlobeNewswire) - "The combination therapy of ECC4703 and semaglutide or tirzepatide resulted in significantly greater weight loss compared to semaglutide or tirzepatide alone. The body composition indicated the additional weight loss was mainly contributed by fat mass loss, with preservation of lean mass."

Preclinical • Obesity

FTIH of ECC4703 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=75 | Completed | Sponsor: Eccogene | Recruiting ➔ Completed | N=54 ➔ 75 | Trial completion date: Jul 2023 ➔ Oct 2023 | Trial primary completion date: Jul 2023 ➔ Oct 2023

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis

FTIH of ECC4703 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Eccogene

New P1 trial • Hepatology • Non-alcoholic Steatohepatitis • APOB